Lightnews — Scholar-powered news

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Badrinath Konety
Can AI drive treatment decision-making in NMIBC?

Growing role of AI in non-muscle invasive bladder cancer care
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 8:44 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Eva Maria Compérat
Role of AI for diagnosis and monitoring #BladderCancer

Emphasizes the broad potential of AI in diagnosing and monitoring

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 8:57 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer

Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 9:37 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer

Presentation discusses if TOMBOLA is practice changing, and more data is needed

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 10:09 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Cédric Lebâcle
Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC?
"pro" side: adapted de-intensification strategy offers several benefits.

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 11:03 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day 1 of #BLADDR24
Dr Kilian Gust
Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC?

CON
While de-intensification and surveillance in low-grade NMIBC may be appealing, it is premature

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social

November 27, 2024 at 11:11 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr. Ben-Max de Ruiter
High-risk BCG-naive NMIBC: should we stick to BCG?

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 11:22 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of hashtag#BLADDR24
Presenter: Dr. Petros Grivas
High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC?

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 11:29 AM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day 1 of #BLADDR24
Dr Celena Scheede-Bergdahl
RC & neobladder
Prehabilitation programme

Prehabilitation in cancer care takes place between diagnosis & start of acute tx, focusing on physical & psychological assessments
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social

November 27, 2024 at 1:19 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The Advanced Prostate Cancer Consensus Conference

@apccc.bsky.social

Study explores how integrated stress response helps #ProstateCancer cells survive, particularly those lacking the p53 tumor suppressor.

@yukselurun.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@oncoalert.bsky.social

www.science.org/doi/10.1126/...

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer

Targeting a cell stress response is synthetic lethal with loss of p53 in prostate cancer cells.

www.science.org

November 27, 2024 at 7:53 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

Gil Morgan MD

@weoncologists.bsky.social

Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨

The OncoAlert Network 🚨 @oncoalert.bsky.social · Nov 26

Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC

#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 26, 2024 at 5:00 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day One of #BLADDR24
Dr Gunhild von Amsberg

Presentation on first-line treatment for advanced urothelial carcinoma highlights the need to balance efficacy, safety, patient characteristics,& QoL.

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

November 27, 2024 at 2:47 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Observational study published in JCO found annual screening mammography reduces risk of late-stage #BreastCancer & improves OS VS biennial or intermittent screening
https://buff.ly/3Z1GBCw

@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@stoverlab.bsky.social
@drsgraff.bsky.social

November 24, 2024 at 2:15 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

The OncoAlert Network along with our partners at @ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg and our Collaborators @APCCC_Lugano @ABCGlobalAll @kidneycan @GuardConsortium @mybsmo @gu_onc Proudly Announce the first 2/3 of our faculty

Register for FREE HERE:
https://buff.ly/3CChgre

November 27, 2024 at 3:38 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

Gil Morgan MD

@weoncologists.bsky.social

Proponents of deferred CN argue a complete pathological response in the 1ry tumor is rare, and even in cases of complete response at metastatic sites, viable tumor cells may remain in the 1ry site. Removing the primary tumor might help eliminate rapidly metastasizing clones
#RenalC24 🚨 #kidneyCancer

The OncoAlert Network 🚨 @oncoalert.bsky.social · Nov 26

Day 1 of #RENALC24
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Register:
https://buff.ly/3Z4aEt3

November 26, 2024 at 4:14 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

Gil Morgan MD

@weoncologists.bsky.social

Dr. Barthelemy,
Moving forward, identifying biomarkers like KIM1 and T-effector gene expression signatures could help predict which patients are more likely to benefit from therapy. The need for predictive algorithms to assess efficacy and toxicity is clear #kidneyCancer
#RenalC24 🚨

The OncoAlert Network 🚨 @oncoalert.bsky.social · Nov 26

Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

#KidneyCancer
Register:
https://buff.ly/3Z4aEt3

November 26, 2024 at 2:12 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Day 1 of #BLADDR24
Dr. Petros Grivas

The concept of withholding radical treatment, such as radical cystectomy (RC) or radiotherapy, for patients with a clinical complete response (cCR) after neoadjuvant or induction systemic therapy is emerging as a potential future approach in #BladderCancer MGt

November 27, 2024 at 4:31 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Study explores how the integrated stress response helps prostate cancer cells survive, particularly those lacking the p53 tumor suppressor. Inhibiting the ISR kinase GCN2 in p53-deficient #ProstateCancer cells disrupts amino acid availability, crucial for purine nucleotide synthesis

The Advanced Prostate Cancer Consensus Conference @apccc.bsky.social · Nov 27

Study explores how integrated stress response helps #ProstateCancer cells survive, particularly those lacking the p53 tumor suppressor.

@yukselurun.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@oncoalert.bsky.social

www.science.org/doi/10.1126/...

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer

Targeting a cell stress response is synthetic lethal with loss of p53 in prostate cancer cells.

www.science.org

November 27, 2024 at 11:02 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

The OncoAlert Network 🚨

@oncoalert.bsky.social

Dear Colleagues
A Pleasure to introduce some our #OncoAlertAF

Associate Faculty 🚨
@elisaagostinetto.bsky.social 🇧🇪
@elisabettabonzano.bsky.social 🇮🇹
@realbowtiedoc.bsky.social 🇺🇸
@biagioricciutimd.bsky.social 🇺🇸
@weoncologists.bsky.social 🇺🇸
@drnataliagandur.bsky.social 🇦🇷

November 21, 2024 at 4:10 PM

Reposted by Maria Natalia Gandur Quiroga, MD, MSc

Gil Morgan MD

@weoncologists.bsky.social

Omitting biopsy in pts with negative MRI results eliminated more than 1/2 of diagnoses of clinically insignificant #ProstateCancer and the associated risk of having incurable cancer diagnosed at screening or as interval cancer was very low

@drnataliagandur.bsky.social @barbaramelao.bsky.social

The OncoAlert Network 🚨 @oncoalert.bsky.social · Nov 17

After median follow-up of 3.9 years, MRI-targeted biopsy group had lower detection rate of clinically insignificant #ProstateCancer compared to the systematic biopsy group (2.8% vs. 4.5%). Out on the New England

https://buff.ly/3YRBzIw